bifeprunox has been researched along with cariprazine in 2 studies
| Studies (bifeprunox) | Trials (bifeprunox) | Recent Studies (post-2010) (bifeprunox) | Studies (cariprazine) | Trials (cariprazine) | Recent Studies (post-2010) (cariprazine) |
|---|---|---|---|---|---|
| 30 | 1 | 12 | 177 | 31 | 152 |
| Protein | Taxonomy | bifeprunox (IC50) | cariprazine (IC50) |
|---|---|---|---|
| D(2) dopamine receptor | Homo sapiens (human) | 0.0017 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albert, JS; Johnstone, S | 1 |
| Gyertyán, I; Kiss, B; Román, V; Sághy, K; Szombathelyi, Z | 1 |
1 review(s) available for bifeprunox and cariprazine
| Article | Year |
|---|---|
Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective.
Topics: Allosteric Regulation; Chemistry, Pharmaceutical; Humans; Ligands; Structure-Activity Relationship | 2017 |
1 other study(ies) available for bifeprunox and cariprazine
| Article | Year |
|---|---|
Cariprazine (RGH-188), a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Cocaine-Related Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Haloperidol; Male; Piperazines; Quinolones; Rats; Rats, Long-Evans; Receptors, Dopamine D2; Secondary Prevention; Substance-Related Disorders | 2013 |